Drugs
Clinical Hold on Aardvark Trial Over Safety Issue
Aardvark Therapeutics said it plans to unblind key clinical trial data on its experimental metabolic drug ARD-101 after FDA imposed a full clinical hold on the program, affecting both its pivotal Phase 3 HERO study and an open-label extension trial. The hold reportedly followed reports of “reversible cardiac